title: Limited advances in therapy of glioblastoma trigger re-consideration of research policy.
abstract: Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed.
authors.affiliation: Mutagenesis Unit, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. Electronic address: guido.frosina@hsanmartino.it.
authors.forename: Guido
authors.initials: G
authors.lastname: Frosina
mesh_terms: D000970:Antineoplastic Agents; D000068258:Bevacizumab / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D055808:Drug Discovery / Q000379:methods; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D012107:Research Design / Q000592:standards*; D059039:Standard of Care
chemical_list: D000970:Antineoplastic Agents; D000068258:Bevacizumab
keywords: Bevacizumab; Bibliometrics; Glioma; Treatment protocol; Treatment quality